Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ardian Catheter · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Ardian Catheter | DEVICE | - |
Inclusion Criteria: * adult \>= 18 years of age * end stage renal disease, undergoing concurrent dialysis treatment * poorly controlled blood pressure on at least 2 antihypertensive drugs * agrees to have the study procedure(s) performed and additional procedures and evaluations, including interven...
The Ardian Catheter is an investigational device being studied for use in End Stage Renal Disease. It is a catheter-based system developed by Medtronic plc. The device is currently in Phase 1 clinical development, with one completed trial evaluating its safety and feasibility in patients with this condition.
The Ardian Catheter is developed by Medtronic plc, a medical technology company traded on the New York Stock Exchange under the ticker MDT. The device is being investigated for potential use in patients with End Stage Renal Disease, and it is currently in Phase 1 clinical development.
The Ardian Catheter is in Phase 1 clinical development. It is an investigational device, not yet approved for commercial use. One Phase 1 trial has been completed, and no active trials are currently listed for this device in the context of End Stage Renal Disease.
The Ardian Catheter has one completed clinical trial, registered under NCT00551304, titled "Native Kidney Denervation in Patients With End Stage Renal Disease." This Phase 1 study was conducted in Australia and Poland, enrolling adults aged 18 years and older with End Stage Renal Disease. The trial was uncontrolled and not randomized.
The Ardian Catheter is a device used in a procedure called renal denervation, which involves disrupting nerves in the kidney. The completed trial NCT00551304 specifically evaluated native kidney denervation in patients with End Stage Renal Disease. However, the Ardian Catheter is the specific device developed by Medtronic for this purpose.